ASCO 2024 Kidney Cancer

Viewing 1-20 of 27 articles

ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?

ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer

ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial

ASCO 2024: Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

ASCO 2024: Partitioned Overall Survival: Comprehensive Analysis of Survival States over 4 Years in CheckMate 9ER Comparing First-Line Nivolumab plus Cabozantinib Versus Sunitinib in Advanced Renal Cell Carcinoma

ASCO 2024: Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial

ASCO 2024: Circulating Kidney Injury Molecule-1 Biomarker Analysis in IMmotion010: A Randomized Phase 3 Study of Adjuvant Atezolizumab vs Placebo in Patients with Renal Cell Carcinoma at Increased Risk of Recurrence After Resection

ASCO 2024: In It for the Long Run: Updated Outcomes From Phase III Trials

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024: Comparative Effectiveness of First-Line Ipilimumab plus Nivolumab Versus Immune Checkpoint Inhibitors + Tyrosine Kinase Inhibitors in Patients with Intermediate or Poor Risk Metastatic Clear Cell Renal Cell Carcinoma

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Safety and Patient-Reported Outcomes of the Randomized Phase 3 CheckMate 67T Trial

ASCO 2024: First-Line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma (RCC): An International Multi-Center Study

ASCO 2024: Association of Machine Learning–derived Histological Features with Transcriptomic Molecular Subtypes in Advanced Renal Cell Carcinoma

ASCO 2024: Comparison of TKI and CPI Strategies as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: Real-World Outcome Data from the German Research Platform CARAT

ASCO 2024: Lenvatinib plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial

ASCO 2024: Changes in Treatment Patterns and Attrition Rates in Patients with Metastatic Clear Cell Renal Cell Carcinoma

ASCO 2024: Matched Tissue and Circulating Tumor DNA (ctDNA) Analysis in Renal Cell Carcinoma (RCC): Results from a Multimodal Real-World Database

ASCO 2024: Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches

1
2